NCT06471738View on ClinicalTrials.gov

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

June 1, 2027

Conditions
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage IV Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Interventions
DRUG

Zanubrutinib

BTK inhibitor

BIOLOGICAL

Rituximab

Monoclonal antibody to CD20

DRUG

Venetoclax

BCL-2 inhibitor

Trial Locations (1)

100853

RECRUITING

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER